These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35252259)

  • 1. IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease.
    Versace AG; Bitto A; Ioppolo C; Aragona CO; La Rosa D; Roberts WN; D'Angelo T; Cinquegrani A; Cirmi S; Irrera N; Navarra M; Corrao S; Gangemi S; Bagnato G
    Front Med (Lausanne); 2022; 9():825567. PubMed ID: 35252259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
    Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
    Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
    Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
    Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
    Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.
    Salaffi F; Carotti M; Di Donato E; Di Carlo M; Ceccarelli L; Giuseppetti G
    PLoS One; 2016; 11(3):e0149240. PubMed ID: 26930658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automatic Quantification of Interstitial Lung Disease From Chest Computed Tomography in Systemic Sclerosis.
    Carvalho ARS; Guimarães AR; Sztajnbok FR; Rodrigues RS; Silva BRA; Lopes AJ; Zin WA; Almeida I; França MM
    Front Med (Lausanne); 2020; 7():577739. PubMed ID: 33102508
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Yanaba K; Yoshizaki A; Asano Y; Kadono T; Sato S
    Clin Rheumatol; 2011 Jun; 30(6):825-30. PubMed ID: 21246230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
    Antoniou KM; Margaritopoulos GA; Goh NS; Karagiannis K; Desai SR; Nicholson AG; Siafakas NM; Coghlan JG; Denton CP; Hansell DM; Wells AU
    Arthritis Rheumatol; 2016 Apr; 68(4):1004-12. PubMed ID: 26636545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis.
    Fukayama M; Yoshizaki A; Fukasawa T; Ebata S; Kuzumi A; Yoshizaki-Ogawa A; Asano Y; Oba K; Sato S
    J Dermatol; 2020 Nov; 47(11):1287-1292. PubMed ID: 32686186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis.
    Tang J; Lei L; Pan J; Zhao C; Wen J
    Rheumatol Int; 2018 Aug; 38(8):1511-1519. PubMed ID: 29846790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis.
    Foeldvari I; Klotsche J; Hinrichs B; Helmus N; Kasapcopur O; Adrovic A; Sztajnbok F; Terreri MT; Anton J; Smith V; Katsicas M; Kostik M; Vasquez-Canizares N; Avcin T; Feldman B; Janarthanan M; Santos MJ; Sawhney S; Schonenberg-Meinema D; Sifuentes-Giraldo WA; Alexeeva E; Appenzeller S; Battagliotti C; Berntson L; Bica B; Costa-Reis P; Eleftheriou D; Kallinich T; Lehman T; Marrani E; Minden K; Nielsen S; Nuruzzaman F; Patwardhan A; Khubchandani R; Stanevicha V; Uziel Y; Torok KS
    Arthritis Care Res (Hoboken); 2022 Mar; 74(3):364-370. PubMed ID: 33141441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease.
    Kuzumi A; Yoshizaki A; Toyama S; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Asano Y; Sato S
    J Dermatol; 2018 Oct; 45(10):1216-1220. PubMed ID: 30004593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
    De Lauretis A; Sestini P; Pantelidis P; Hoyles R; Hansell DM; Goh NS; Zappala CJ; Visca D; Maher TM; Denton CP; Ong VH; Abraham DJ; Kelleher P; Hector L; Wells AU; Renzoni EA
    J Rheumatol; 2013 Apr; 40(4):435-46. PubMed ID: 23378460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.